Kenvue Inc. Common Stock vs Nike Inc — how do they compare? Kenvue Inc. Common Stock trades at $17.68 (market cap $34.06B), while Nike Inc trades at $34.83 (market cap $51.60B). The key difference: Nike Inc is the larger of the two by market cap, and Kenvue Inc. Common Stock pays the higher dividend (4.74%). Which is the better fit depends on your goals.
| KVUE | NKE | |
|---|---|---|
Market Cap | $34.06B | $51.60B |
Volume | 23,267,228 | 43,506,062 |
Sector | Consumer Staples | Consumer Cyclical |
52-Week High | $19.83 | $69.68 |
52-Week Low | $14.11 | $33.87 |
Enterprise Value | $41.56B | $54.30B |
Dividend Yield | 4.74% | 4.72% |
Typical Hold Time | — | 155 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nike's stock trades at $34.36, down 0.72% with a bearish technical outlook. The company reported $46.31B in revenue for 2025 with a 6.74% net margin, though earnings have beaten expectations in recent quarters. Analyst consensus remains positive with a $36.98 price target, while recent news highlights challenges in China and inventory management.
Nike faces near-term headwinds from slowing revenue growth and margin pressure, but strong brand positioning and consistent earnings beats provide upside potential. Key risks include consumer demand weakness and competitive pressures, while institutional sentiment remains cautiously optimistic for a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →